Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer.

Chest - 1 Jun 2012

Zhu Xiao, Lin Marie C M, Fan Wenguo, Tian Linwei, Wang Jinlong, Ng Samuel S, Wang Min, Kung Hsiangfu, Li Dongpei

Abstract excerpt

BACKGROUND: Glucose-regulated protein 78 (GRP78) is involved in not only the progression of non-small cell lung cancer (NSCLC) but also chemotherapeutic effects. We hypothesized that an intronic polymorphism (rs430397G>A) in GRP78 affects survival among patients with NSCLC treated with platinum-based chemotherapy. METHODS: Blood samples of patients with advanced NSCLC (IIIB/IV) were maintained in our specimen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chi-Square Distribution
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endoplasmic Reticulum Chaperone BiP

Share to Heat-Shock Proteins

Share to Introns

Share to Proportional Hazards Models

Share to Real-Time Polymerase Chain Reaction

Share to Survival Rate

Source

Identifiers

PMID: 21940774
DOI: 10.1378/chest.11-0469

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer.PMID 21940774Read ↗

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.Semantic proximity Read ↗

Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.Semantic proximity Read ↗

Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.Semantic proximity Read ↗

GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients.Semantic proximity Read ↗

A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.Semantic proximity Read ↗

The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.Semantic proximity Read ↗

Gene expression and single nucleotide polymorphism of ATP7B are associated with platinum-based chemotherapy response in non-small cell lung cancer patientsSemantic proximity Read ↗

Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.Semantic proximity Read ↗

Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

Polymorphisms in solute carrier genes (SLC19A1, SLCO1B1, and SLCO1B3) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.Semantic proximity Read ↗

Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.